+------------------------------------------------------------------------------+
BN 12/19 16:19 *ASTRAZENECA LOSES BID TO HALT HANMI'S COPY OF NEXIUM DRUG BFW 12/19 16:19 *ASTRAZENECA LOSES APPEALS COURT FIGHT OVER HANMI’S NEXIUM COPY BN 12/19 16:18 *ASTRAZENECA LOSES APPEALS COURT FIGHT OVER HANMI'S NEXIUM COPY
+------------------------------------------------------------------------------+
AstraZeneca Loses Appeals Court Fight Over Hanmi’s Nexium Copy 2013-12-19 16:20:52.806 GMT
By Susan Decker Dec. 19 (Bloomberg) -- AstraZeneca Plc lost an appeals court ruling today that will enable Hanmi Pharm Co. to sell a copy of the heartburn treatment Nexium. AstraZeneca’s patent on the drug is limited to a specifically named salt, the U.S. Court of Appeals for the Federal Circuit in Washington said in an opinion posted on its website. AstraZeneca had conceded that Hanmi’s version wouldn’t infringe the patent if the appeals court ruled in that way. Hanmi has been barred from selling its copy of Nexium until the decision was released today.
Link to Company News:{008930 KS <Equity> CN <GO>} Link to Company News:{AZN LN <Equity> CN <GO>} Link to Company News:{128940 KS <Equity> CN <GO>}
For Related News and Information: Top Stories:{TOP<GO>}
To contact the reporter on this story: Susan Decker in Washington at +1-202-624-1941 or sdecker1@bloomberg.net
To contact the editor responsible for this story: Elizabeth Wasserman at +1-202-624-1954 or ewasserman2@bloomberg.net